The estimated Net Worth of Robert J Wollin is at least 74 千$ dollars as of 14 January 2024. Mr Wollin owns over 5,000 units of MeiraGTx plc stock worth over 73,969$ and over the last 4 years he sold MGTX stock worth over 0$.
Mr has made over 4 trades of the MeiraGTx plc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of MGTX stock worth 20,800$ on 14 January 2024.
The largest trade he's ever made was exercising 15,000 units of MeiraGTx plc stock on 7 January 2024 worth over 62,400$. On average, Mr trades about 4,429 units every 86 days since 2021. As of 14 January 2024 he still owns at least 17,781 units of MeiraGTx plc stock.
You can see the complete history of Mr Wollin stock trades at the bottom of the page.
Robert J. Wollin J.D. is the Gen. Counsel & Sec. at MeiraGTx plc.
Mr D is 44, he's been the Gen. Counsel & Sec. of MeiraGTx plc since . There are 16 older and 1 younger executives at MeiraGTx plc. The oldest executive at MeiraGTx Holdings plc is Arnold Levine, 80, who is the Independent Director.
Robert's mailing address filed with the SEC is 450 EAST 29TH STREET, 14TH FLOOR, NEW YORK, NY, 10016.
Over the last 6 years, insiders at MeiraGTx plc have traded over 7,031,523$ worth of MeiraGTx plc stock and bought 9,222,038 units worth 85,317,799$ . The most active insiders traders include Advisors Llcperceptive Life...、Joel S Marcus、Life Sciences Master Fund L.... On average, MeiraGTx plc executives and independent directors trade stock every 33 days with the average trade being worth of 672,044$. The most recent stock trade was executed by Advisors Llcperceptive Life... on 12 August 2024, trading 1,250,000 units of MGTX stock currently worth 5,000,000$.
meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
MeiraGTx plc executives and other stock owners filed with the SEC include: